Prescription medication · Selective MAO-B Inhibitor
selegiline
Also sold as Emsam. Selegiline is used to help people with Parkinson's disease.
Data updated 2026-05-15
- 2,896
- FDA reportsLightly reported
- 9
- InteractionsFew interactions
- 99% less
- Generic vs brandHuge savings
- $68.68
- Brand price (NADAC)
What the data shows
selegiline (Emsam) is a prescription Selective MAO-B Inhibitor, among the least-reported drugs the FDA tracks (2,896 FDA reports), whose generic costs a fraction of the brand (about 99% less).
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
selegiline (Emsam) is a prescription Selective MAO-B Inhibitor. Selegiline is used to help people with Parkinson's disease.
Selegiline is a medicine that can help manage Parkinson's disease. It is used along with levodopa/carbidopa when that medicine is not working as well as it used to.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$68.68/unit
Generic Price
$0.61/unit
Generic Savings
99%
Generic Available
Yes (6 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Selegiline is used to help people with Parkinson's disease.
Common side effects
Nausea, Dizziness, Light-headedness
Key warnings
Taking selegiline with meperidine (Demerol) is dangerous and can cause serious reactions.
The sections below are summarized in plain English from selegiline's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Selegiline is a selective MAO-B inhibitor. It works by blocking an enzyme in the brain that breaks down dopamine. This helps to increase the amount of dopamine available, which can improve motor control in Parkinson's disease.
Side Effects (from patient reports)
Based on 2,896 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for selegiline, by number of reports
- Insomnia
Insomnia
184 reports
- Application Site Erythema
Application Site Erythema
183 reports
- Dizziness
Dizziness
168 reports
- Hallucination
Hallucination
166 reports
- Fall
Fall
137 reports
- Dyskinesia
Dyskinesia
133 reports
- Depression
Depression
128 reports
- Anxiety
Anxiety
126 reports
- Application Site Rash
Application Site Rash
126 reports
- Drug Interaction
Drug Interaction
123 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for selegiline each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where selegiline sits
selegiline has more FDA adverse-event reports than 17% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is selegiline; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 2,896 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2003–2025.
Total Reports
2,896
Reports Mentioning Death
164
5.7% of reports — not proof of cause
Hospitalization Reports
570
Top Indication
Depression
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | INSOMNIA | 184 |
| 3 | APPLICATION SITE ERYTHEMA | 183 |
| 4 | DIZZINESS | 168 |
| 5 | HALLUCINATION | 166 |
| 6 | FALL | 137 |
| 7 | DYSKINESIA | 133 |
| 8 | DEPRESSION | 128 |
| 9 | ANXIETY | 126 |
| 10 | APPLICATION SITE RASH | 126 |
| 11 | DRUG INTERACTION | 123 |
| 12 | APPLICATION SITE PRURITUS | 120 |
| 13 | TREMOR | 116 |
| 14 | FATIGUE | 112 |
| 15 | NAUSEA | 111 |
| 16 | HEADACHE | 107 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Taking selegiline with meperidine (Demerol) is dangerous and can cause serious reactions. Also, use caution when taking selegiline with tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs) due to the risk of severe toxicity. One patient had a hypertensive crisis when taking selegiline with a sympathomimetic medicine (ephedrine).
Known Drug Interactions
Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact Concomitant use of PRISTIQ with other serotonergic drugs increases the risk of serotonin syndrome.
Mechanism: These medications both raise serotonin levels in your body. Combining them can lead to too much serotonin, which can cause a dangerous reaction.
Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.
Mechanism: Taking these medications together can cause serotonin levels to become dangerously high, leading to a condition called serotonin syndrome.
Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact The concomitant use of serotonergic drugs with mirtazapine increases the risk of serotonin syndrome.
Mechanism: Both mirtazapine and selegiline increase the amount of serotonin in your brain. Combining them can lead to a toxic buildup of this chemical.
Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Pimozide and Thioridazine Clinical Impact Increased plasma concentrations of pimozide and thioridazine, drugs with a narrow therapeutic index, may increase the risk of QTc prolongation and ventricular arrhythmias.
Mechanism: Taking these two medicines together can cause a dangerous buildup of a brain chemical called serotonin.
Examples: isocarboxazid, moclobemide, phenelzine, selegiline, tranylcypromine Other Serotonergic Drugs Clinical Impact: The concomitant use of serotonergic drugs including trazodone and other serotonergic drugs increases the risk of serotonin syndrome.
Mechanism: These medications both raise serotonin levels, and taking them at the same time increases the risk of a toxic reaction.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I take more than 10 mg of selegiline per day?
Can selegiline be taken without levodopa/carbidopa?
Will selegiline cure my Parkinson's disease?
How long does it take for selegiline to start working?
Can I drink alcohol while taking selegiline?
What should I do if I experience side effects?
Can I stop taking selegiline suddenly?
Does selegiline interact with other medicines?
What if I forget to refill my prescription?
Can I drive while taking selegiline?
What are the common side effects of selegiline?
Does selegiline interact with other medications?
What drug class is selegiline?
Is there a generic version of selegiline?
What pregnancy or breastfeeding source fields are listed for selegiline?
Related Medications in Selective MAO-B Inhibitor
Other drugs grouped near selegiline - same-class peers and common alternatives.
acamprosate
Campral
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking.
Compare with selegiline →
alprazolam
Xanax
Alprazolam (Xanax) is a medication that can help you with anxiety and panic disorders.
Compare with selegiline →
amitriptyline
Elavil
Amitriptyline is a medicine used to treat depression.
Compare with selegiline →
amphetamine/dextroamphetamine
Adderall, Adderall XR
Adderall XR is a stimulant medicine.
Compare with selegiline →
aripiprazole
Abilify
Aripiprazole (Abilify) is a medicine used to treat certain mental disorders and mood problems.
Compare with selegiline →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for selegiline: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 2,896.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 5.66%.
- nabumetone Δ 0.03 pts · 6,319 reports · Nonsteroidal Anti-Inflammatory Drug (NSAID) 5.70%death share
- insulin glargine Δ 0.06 pts · 236,147 reports · Long-Acting Insulin 5.60%death share
- potassium citrate Δ 0.06 pts · 5,207 reports · Urinary Alkalinizer 5.72%death share
- rufinamide Δ 0.07 pts · 2,477 reports · Anticonvulsant (Triazole) 5.73%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on selegiline
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for selegiline
The FDA label for selegiline (sold under brand names such as Emsam) classifies it as a prescription-only medication in the Selective MAO-B Inhibitor class. Selegiline is used to help people with Parkinson's disease. Official labeling lists 10 commonly reported side effects, including Nausea, Dizziness, Light-headedness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 2,896 voluntary reports. The database also lists 9 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $0.61 versus $68.68 for the brand - a 99% generic savings.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: November 24, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages